Pacad Investment Ltd. Acquires 4,900 Shares of GlaxoSmithKline PLC (GSK)

Pacad Investment Ltd. increased its holdings in GlaxoSmithKline PLC (NYSE:GSK) by 111.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,300 shares of the pharmaceutical company’s stock after purchasing an additional 4,900 shares during the quarter. Pacad Investment Ltd.’s holdings in GlaxoSmithKline PLC were worth $401,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Bingham Osborn & Scarborough LLC bought a new stake in shares of GlaxoSmithKline PLC in the second quarter worth $311,000. 10 15 Associates Inc. lifted its holdings in GlaxoSmithKline PLC by 6.4% in the first quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock valued at $10,022,000 after buying an additional 14,247 shares during the period. Lincluden Management Ltd. lifted its holdings in GlaxoSmithKline PLC by 1.7% in the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock valued at $5,095,000 after buying an additional 1,990 shares during the period. Anchor Capital Advisors LLC lifted its holdings in GlaxoSmithKline PLC by 9.6% in the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock valued at $25,858,000 after buying an additional 53,894 shares during the period. Finally, BlueCrest Capital Management Ltd lifted its holdings in GlaxoSmithKline PLC by 293.5% in the first quarter. BlueCrest Capital Management Ltd now owns 51,157 shares of the pharmaceutical company’s stock valued at $2,157,000 after buying an additional 38,157 shares during the period. 9.28% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Pacad Investment Ltd. Acquires 4,900 Shares of GlaxoSmithKline PLC (GSK)” was posted by BBNS and is owned by of BBNS. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://baseballnewssource.com/markets/pacad-investment-ltd-has-401000-holdings-in-glaxosmithkline-plc-gsk/1601017.html.

Shares of GlaxoSmithKline PLC (NYSE GSK) opened at 40.58 on Friday. The company’s 50 day moving average is $39.76 and its 200-day moving average is $41.75. The stock has a market capitalization of $99.18 billion, a PE ratio of 40.10 and a beta of 1.03. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. On average, equities analysts predict that GlaxoSmithKline PLC will post $2.87 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be given a dividend of $0.491 per share. This represents a $1.96 annualized dividend and a dividend yield of 4.84%. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio is presently 197.00%.

Several equities analysts recently issued reports on GSK shares. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. ValuEngine lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub lowered shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Finally, Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $44.67.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game


Leave a Reply

 
© 2006-2017 BBNS.